{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:00:26Z","timestamp":1792555226855,"version":"4.5.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","funder":[{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["MD014110"],"award-info":[{"award-number":["MD014110"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2021,8]]},"abstract":"Abstract<\/jats:title>\n \n Key Points<\/jats:title>\n \n \n \n \n TGF-\n \u03b2<\/jats:italic>\n receptor 3 (TGFBR3) staining identifies a novel type of membranous nephropathy (MN).\n <\/jats:p>\n <\/jats:list-item>\n \n TGFBR3-associated MN is enriched in patients with membranous lupus nephritis with similar characteristics as exostosin 1\/2- and neural cell adhesion molecule 1\u2013associated MN.<\/jats:p>\n <\/jats:list-item>\n \n Identification of TGFBR3-associated MN should alert the clinician to evaluate for underlying autoimmune disease.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n \n Membranous lupus nephritis (MLN) comprises 10%\u201315% of lupus nephritis and increases morbidity and mortality of patients with SLE through complications of nephrotic syndrome and chronic kidney failure. Identification of the target antigens in MLN may enable noninvasive monitoring of disease activity, inform treatment decisions, and aid in prognostication, as is now possible for idiopathic MN caused by antibodies against the phospholipase A2 receptor. Here, we show evidence for type III TGF-\n \u03b2<\/jats:italic>\n receptor (TGFBR3) as a novel biomarker expressed in a subset of patients with MLN.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Mass spectrometry was used for protein discovery through enrichment of glomerular proteins by laser capture microdissection and through elution of immune complexes within MLN biopsy specimens. Colocalization with IgG within glomerular immune deposits from patients and disease controls was evaluated by confocal microscopy. Immunostaining of consecutive case series was used to determine the overall frequency in MN and MLN.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n TGFBR3 was found to be enriched in glomeruli and coimmunoprecipitated with IgG within a subset of MLN biopsy specimens by mass spectrometry. Staining of consecutive MN cases without clinical evidence of SLE did not show TGFBR3 expression (zero of 104), but showed a 6% prevalence in MLN (11 of 199 cases). TGFBR3 colocalized with IgG along the glomerular basement membranes in TGFBR3-associated MN, but not in controls.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Positive staining for TGFBR3 within glomerular immune deposits represents a distinct form of MN, substantially enriched in MLN. A diagnosis of TGFBR3-associated MN can alert the clinician to search for an underlying autoimmune disease.<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0001492021","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T16:15:11Z","timestamp":1623428111000},"page":"1275-1286","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":63,"title":["Transforming Growth Factor Beta Receptor 3 (TGFBR3)\u2013Associated Membranous Nephropathy"],"prefix":"10.34067","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8988-8998","authenticated-orcid":false,"given":"Tiffany N.","family":"Caza","sequence":"first","affiliation":[{"name":"Arkana Laboratories, Little Rock, Arkansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar I.","family":"Hassen","sequence":"additional","affiliation":[{"name":"Arkana Laboratories, Little Rock, Arkansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5284-7284","authenticated-orcid":false,"given":"Daniel J.","family":"Kenan","sequence":"additional","affiliation":[{"name":"Arkana Laboratories, Little Rock, Arkansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4089-5008","authenticated-orcid":false,"given":"Aaron","family":"Storey","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, Arkansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4342-4762","authenticated-orcid":false,"given":"John M.","family":"Arthur","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, Arkansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Herzog","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, Arkansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick D.","family":"Edmondson","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, Arkansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. David","family":"Bourne","sequence":"additional","affiliation":[{"name":"Arkana Laboratories, Little Rock, Arkansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence H.","family":"Beck","sequence":"additional","affiliation":[{"name":"Boston University Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Larsen","sequence":"additional","affiliation":[{"name":"Arkana Laboratories, Little Rock, Arkansas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"key":"B1-20250825","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0272-6386(12)80957-7","article-title":"Lupus nephritis: Prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL)","volume":"19","author":"Schieppati","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"B2-20250825","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/ndt\/17.10.1771","article-title":"Factors affecting outcome and prognosis in membranous lupus nephropathy","volume":"17","author":"Mercadal","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"B3-20250825","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1681\/ASN.2008060665","article-title":"Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy","volume":"20","author":"Austin","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B4-20250825","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00281-007-0091-2","article-title":"Target antigens and nephritogenic antibodies in membranous nephropathy: Of rats and men","volume":"29","author":"Ronco","year":"2007","journal-title":"Semin Immunopathol"},{"key":"B5-20250825","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1681\/ASN.2020071082","article-title":"New \u2018antigens\u2019 in membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B6-20250825","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"B7-20250825","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"B8-20250825","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/modpathol.2016.32","article-title":"THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity","volume":"29","author":"Larsen","year":"2016","journal-title":"Mod Pathol"},{"key":"B9-20250825","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","article-title":"NELL1 is a target antigen in malignancy-associated membranous nephropathy","volume":"99","author":"Caza","year":"2021","journal-title":"Kidney Int"},{"key":"B10-20250825","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"B11-20250825","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2020.05.030","article-title":"Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients","volume":"98","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"B12-20250825","article-title":"Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy [published online ahead of print May 5, 2021]","author":"Al-Rabadi","journal-title":"J Am Soc Nephrol"},{"key":"B13-20250825","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1681\/ASN.2020081165","article-title":"Protocadherin 7-associated membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B14-20250825","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.kint.2020.09.016","article-title":"Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis","volume":"100","author":"Caza","year":"2021","journal-title":"Kidney Int"},{"key":"B15-20250825","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nmeth.1322","article-title":"Universal sample preparation method for proteome analysis","volume":"6","author":"Wi\u015bniewski","year":"2009","journal-title":"Nat Methods"},{"key":"B16-20250825","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/modpathol.3800239","article-title":"Practice guidelines for the renal biopsy","volume":"17","author":"Walker","year":"2004","journal-title":"Mod Pathol"},{"key":"B17-20250825","doi-asserted-by":"crossref","first-page":"dev164038","DOI":"10.1242\/dev.164038","article-title":"Single-cell analysis of progenitor cell dynamics and lineage specification in the human fetal kidney","volume":"145","author":"Menon","year":"2018","journal-title":"Development"},{"key":"B18-20250825","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1681\/ASN.V9122253","article-title":"Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis","volume":"9","author":"Yamamoto","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"B19-20250825","doi-asserted-by":"crossref","first-page":"189.12","DOI":"10.4049\/jimmunol.196.Supp.189.12","article-title":"TGF-\u03b2 receptor 3 (betaglycan) regulates Th1 differentiation and T dependent B cell responses","volume":"196","author":"Raman","year":"2016","journal-title":"J Immunol"},{"key":"B20-20250825","doi-asserted-by":"crossref","first-page":"43.6","DOI":"10.4049\/jimmunol.200.Supp.43.6","article-title":"T cell restricted TGF-\u03b2R3 (betaglycan) null mice develop exacerbated experimental autoimmune encephalomyelitis (EAE) associated with expanded generation of Th1 cells","volume":"200","author":"Duesman","year":"2018","journal-title":"J Immunol"},{"key":"B21-20250825","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/exostosin 2-associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J Am Soc Nephrol"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0001492021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:02:37Z","timestamp":1786478557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0001492021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0001492021","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"2021-03-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}